NSCLC
Why trials studying NSCLC stopped, in this sample of ClinicalTrials.gov.
19 stopped trials with a clear reason; 95% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding or business | 14 | 74% |
| slow enrollment | 3 | 16% |
| drug or device supply | 1 | 5% |
| safety | 1 | 5% |
Trials
- Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
NCT06552000 · WITHDRAWN · funding or business
“Sponsor deprioritized the study and made the choice to close the study.” - An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
NCT06332300 · WITHDRAWN · drug or device supply
“The study drug, Famitinib, was not marketed and the drug was not available.” - A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT06094296 · TERMINATED · funding or business
“Business objectives have changed” - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
NCT06090318 · WITHDRAWN · funding or business
“Sponsor Decision” - A Biomarker Screening Protocol for Participants With Solid Tumors
NCT05891197 · TERMINATED · funding or business
“Pipeline Reprioritization” - Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
NCT05693090 · WITHDRAWN · funding or business
“This study was withdrawn due to a strategic business decision; no patients were enrolled.” - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574 · TERMINATED · funding or business
“Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.” - Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
NCT04939701 · TERMINATED · funding or business
“The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.” - Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
NCT05207371 · TERMINATED · funding or business
“Decision based on the development company's development policy” - A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
NCT04849273 · TERMINATED · safety
“Adverse change in the risk/benefit.” - A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
NCT04746924 · TERMINATED · funding or business
“This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” - Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
NCT04549025 · TERMINATED · funding or business
“The Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.” - Study of Poziotinib in Japanese Patients With NSCLC
NCT04402008 · TERMINATED · funding or business
“Business decision, not related to safety.” - Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
NCT04044170 · TERMINATED · funding or business
“Study termination by the Sponsor” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
NCT04106167 · TERMINATED · funding or business
“This study was terminated by the Sponsor.” - Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study
NCT03606070 · TERMINATED · slow enrollment
“Lack of inclusion” - A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
NCT03246854 · TERMINATED · funding or business
“No more funding” - Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
NCT01222572 · TERMINATED · slow enrollment
“Slow accrual due to restrictive eligibility criteria” - Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
NCT02179567 · TERMINATED · slow enrollment
“Terminated due to poor accrual”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.